Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Trials
Collaboration
Funding
Research Alliance: Page 2
Taking time out for genetic testing in acute myeloid leukemia may be OK
By
Emily Hayes
The retrospective real-world study evaluated outcomes for AML patients included in the Study Alliance Leukemia (SAL) AML registry, which includes 46 treatment centers in Germany. Researchers set out to evaluate how differences in the length of time from diagnosis to start of treatment correlated with overall survival and other key outcomes in patients newly diagnosed with and previously untreated for AML.
June 4, 2020
Europe raises 7.4B euros for coronavirus response
By
LabPulse.com staff writers
The fundraising event was held in response to a call for more money to respond to COVID-19 by the Global Preparedness Monitoring Board (GPMB), a body convened by the World Health Organization (WHO) and World Bank Group.
May 4, 2020
WHO steps on the gas for collaboration on treatments and tests
By
LabPulse.com staff writers
The organization said that heads of state and global health leaders have committed to accelerating the development and production of new vaccines, tests, and treatments for COVID-19. The entire world is at risk as long as the virus threatens any country, the WHO noted. To date, there have been more than 2.4Â million cases globally and 160,000 deaths.
April 23, 2020
Clinical laboratory market enjoys steady growth, exceeds $121B
By
Bruce Carlson
Clinical laboratories are an essential part of the health industry, Kalorama noted. It is estimated that 70% to 80% of diagnoses by physicians result from laboratory tests, and clinical laboratory services are involved in 100% of patient care plans in oncology indications.Source: Kalorama Information.
February 17, 2020
Gestalt touts tie-ups for cancer image workflow
By
LabPulse.com staff writers
Gestalt markets the PathFlow software platform for managing pathology images in laboratories. MindPeak has a software program for research use only called BreastAI to evaluate breast cancer immunohistochemistry tests. The partners are developing an integrated workflow that allows pathologists to send regions of interest on digital breast cancer images to MindPeak, access AI algorithms quickly, and get annotated results back in real-time. This will result in improved efficiency, with faster turnaround times in labs, according to the companies.
October 6, 2019
Previous Page
Page 2 of 2